Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Vinpocetine

MedGen UID:
28883
Concept ID:
C0059752
Organic Chemical; Pharmacologic Substance
2.

Cilostazol

A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. [from NCI]

MedGen UID:
63309
Concept ID:
C0055729
Organic Chemical; Pharmacologic Substance
3.

Sclerosis

A pathological hardening or thickening of tissue, especially that of the interstitial substance. [from NCI]

MedGen UID:
48587
Concept ID:
C0036429
Pathologic Function
4.

Rolipram

A phosphodiesterase 4 inhibitor with antidepressant properties. [from MeSH]

MedGen UID:
34443
Concept ID:
C0073561
Organic Chemical; Pharmacologic Substance
5.

Phosphodiesterase inhibitor

Any substance that inhibits phosphodiesterase, an enzyme that catalyzes the breaking of a phosphodiester bond. Usually, this refers to cyclic nucleotide phosphodiesterase, an enzyme that breaks the phosphodiester bond in the second messenger molecules cAMP and cGMP. Inhibition of cyclic nucleotide phosphodiesterase can be used to affect vasodilation. [from NCI]

MedGen UID:
10727
Concept ID:
C0031638
Pharmacologic Substance
6.

Multiple sclerosis

A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers. [from NCI]

MedGen UID:
10123
Concept ID:
C0026769
Disease or Syndrome
7.

Anti-inflammatory preparations

Substances that reduce or suppress INFLAMMATION. [from MeSH]

MedGen UID:
1574
Concept ID:
C0003209
Pharmacologic Substance
8.

Multiple sclerosis susceptibility

Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.Multiple sclerosis usually begins in early adulthood, between ages 20 and 40. The symptoms vary widely, and affected individuals can experience one or more effects of nervous system damage. Multiple sclerosis often causes sensory disturbances in the limbs, including a prickling or tingling sensation (paresthesia), numbness, pain, and itching. Some people experience Lhermitte sign, which is an electrical shock-like sensation that runs down the back and into the limbs. This sensation usually occurs when the head is bent forward. Problems with muscle control are common in people with multiple sclerosis. Affected individuals may have tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness or partial paralysis of the muscles of the limbs, difficulty walking, or poor bladder control. Multiple sclerosis is also associated with vision problems, such as blurred or double vision or partial or complete vision loss. Infections that cause fever can make the symptoms worse.There are several forms of multiple sclerosis: relapsing-remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS. The most common is the relapsing-remitting form, which affects approximately 80 percent of people with multiple sclerosis. Individuals with this form of the condition have periods during which they experience symptoms, called clinical attacks, followed by periods without any symptoms (remission). The triggers of clinical attacks and remissions are unknown. After about 10 years, relapsing-remitting MS usually develops into another form of the disorder called secondary progressive MS. In this form, there are no remissions, and symptoms of the condition continually worsen.Primary progressive MS is the next most common form, affecting approximately 10 to 20 percent of people with multiple sclerosis. This form is characterized by constant symptoms that worsen over time, with no clinical attacks or remissions. Primary progressive MS typically begins later than the other forms, around age 40.Progressive relapsing MS is a rare form of multiple sclerosis that initially appears like primary progressive MS, with constant symptoms. However, people with progressive relapsing MS also experience clinical attacks of more severe symptoms. [from GTR]

MedGen UID:
429785
Concept ID:
CN031763
Disease or Syndrome
9.

Remission phase

An abatement in intensity or degree (as in the manifestations of a disease). [from NCI]

MedGen UID:
154255
Concept ID:
C0544452
Finding
10.

Negative

An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. [Note: Negative does not necessarily imply the complete absence of the specified item.].  [from HL7]

MedGen UID:
61377
Concept ID:
C0205160
Finding
11.

Inhibition

MedGen UID:
5809
Concept ID:
C0021469
Molecular Function
12.

Molecular Mechanisms of Pharmacological Action

Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY. [from MeSH]

MedGen UID:
226255
Concept ID:
C1258062
Molecular Function
13.

Indole Alkaloids

Group of alkaloids containing a benzylpyrrole group (derived from TRYPTOPHAN) [from MeSH]

MedGen UID:
181899
Concept ID:
C0949738
Organic Chemical; Pharmacologic Substance
14.

Mediator of inflammation

The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC). [from MeSH]

MedGen UID:
66209
Concept ID:
C0243042
Pharmacologic Substance
15.

ZK-62711

MedGen UID:
56182
Concept ID:
C0149429
Organic Chemical; Pharmacologic Substance
16.

Vinca alkaloid

A group of indole-indoline dimers which are ALKALOIDS obtained from the VINCA genus of plants. They inhibit polymerization of TUBULIN into MICROTUBULES thus blocking spindle formation and arresting cells in METAPHASE. They are some of the most useful ANTINEOPLASTIC AGENTS. [from MeSH]

MedGen UID:
22648
Concept ID:
C0042672
Organic Chemical; Pharmacologic Substance
17.

Enzyme inhibitor

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. [from MeSH]

MedGen UID:
8652
Concept ID:
C0014432
Pharmacologic Substance
18.

Alseroxylon

An alkaloidal extract from RAUWOLFIA. [from MeSH]

MedGen UID:
8001
Concept ID:
C0002340
Biologically Active Substance; Organic Chemical; Pharmacologic Substance
19.

Alkaloid

A family or group of nitrogen-containing base compounds primarily derived from plant and animal sources. Many alkaloids are used medicinally, including cancer therapy. [from NCI]

MedGen UID:
7968
Concept ID:
C0002062
Organic Chemical; Pharmacologic Substance
20.

Indole

A class of bicyclic organic compounds composed of a phenyl ring attached to a nitrogen-containing pyrrole ring. The chemical structure is C1(NC=C2)=C2C=CC=C1. [from NCI_CRCH]

MedGen UID:
5785
Concept ID:
C0021236
Organic Chemical; Pharmacologic Substance
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center